Agency liposomal drugs on clinical course chronic cardio-renal syndrome for hypertensive patients with chronic glomerulonephritis with cardiovascular disturbances
Agency liposomal drugs on clinical course chronic cardio-renal syndrome for hypertensive patients with chronic glomerulonephritis with cardiovascular disturbances is in-process estimated. It is displayed, that such treatments contributes in frequency reduction supraventricular extrasystole and sinus to a tachycardia, silent myocardial ischemia, systole-diastolic dysfunction, mean systolic pressure in a pulmonary artery, proteinuria, glomerular filtration rate and amelioration of indexes of lipidogram.